Abbott Laboratories
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B | $4.50B | $3.69B | $2.37B |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $1.43B | $1.34B | $1.28B | $1.25B | $1.49B | $1.20B | $1.08B | $1.10B |
| Amortization | $1.68B | $1.88B | $1.97B | $2.01B | $2.05B | $2.13B | $1.94B | $2.18B |
| Stock-Based Compensation | $664.0M | $673.0M | $644.0M | $685.0M | $640.0M | $546.0M | $519.0M | $477.0M |
| Net Cash from Operating Activities | $9.57B | $8.56B | $7.26B | $9.58B | $10.53B | $7.90B | $6.14B | $6.30B |
| Investing Activities | ||||||||
| Capital Expenditures | $2.17B | $2.21B | $2.20B | $1.78B | $1.89B | $2.18B | $1.64B | $1.39B |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-2.42B | $-2.34B | $-3.13B | $-1.74B | $-2.01B | $-2.22B | $-1.82B | $-1.36B |
| Financing Activities | ||||||||
| Dividends Paid | $4.12B | $3.84B | $3.56B | $3.31B | $3.20B | $2.56B | $2.27B | $1.97B |
| Stock Repurchases | $893.0M | $1.30B | $1.23B | $3.80B | $2.30B | $403.0M | $718.0M | $238.0M |
| Net Cash from Financing Activities | $-6.31B | $-5.40B | $-7.09B | $-7.64B | $-5.49B | $-2.78B | $-4.29B | $-10.39B |
| Net Change in Cash | $906.0M | $720.0M | $-2.99B | $83.0M | $2.96B | $2.98B | $16.0M | $-5.56B |
| Free Cash Flow | $7.40B | $6.35B | $5.06B | $7.80B | $8.65B | $5.72B | $4.50B | $4.91B |